EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis

Gilson Dorneles, Ellen Algeri, Gerhard Lauterbach, Marcelo Pereira, Brigida Fernandes

Experimental and Clinical Endocrinology & Diabetes · 01.06.2024 · 132 (06) · 316-327

DOI: 10.1055/a-2303-8558 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, erschienen am 01.06.2024. Verfasst von Gilson Dorneles und 4 weiteren Autor:innen. Beteiligte Einrichtung: Responsabilidade Social. Hospital Moinhos de Vento. Porto Alegre/Brazil. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Obesity, Overweight. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Ministério da Saúde.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To evaluate the efficacy and safety of once-weekly subcutaneous semaglutide treatment in overweight or obese patients without type 2 diabetes.

Methods

Randomized clinical trials that assessed the impact of once-weekly semaglutide on body weight and safety outcomes in overweight or obese patients were retrieved from PubMed, EMBASE, and Lilacs up to November 2023. Risk of bias was assessed with RoB 2.0, and certainty of evidence (CoE) with GRADE. A random-effects meta-analysis was conducted.

Results

Ten publications, with 22.155 patients, were included. Semaglutide decreased relative body weight (MD: −11.80; 95%CI: −13.53 to −10.07; CoE: High), absolute body weight (MD: −11.58; 95%CI: −13.25 to −9.90; CoE: High) and BMI (MD: −4.15; 95%CI: −4.85 to −3.45; CoE: High). Semaglutide also increased the proportion of patients who achieved 5%, 10%, and 15% of weight loss ([weight loss≥5%: RR 2.29, 95% CI: 1.88 to 2.80; CoE: High]; [weight loss≥10%: RR 4.54, 95% CI: 3.45 to 5.98; CoE: High]; [weight loss≥15%: RR 8.29, 95%CI: 5.54 to 12.39; CoE: High]). Semaglutide leads to small risk to adverse events (RR: 1.03; 95%CI: 1 to 1.06; CoE: High), no difference in the serious adverse events (RR: 1.07; 95%CI: 0.70 to 1.62; CoE: Low), but increases in the risk to discontinued treatment (RR: 2.03; 95%CI: 1.87 to 2.20; CoE: High) and gastrointestinal adverse events (RR: 3.26; 95%CI: 1.99 to 5.34; CoE: Moderate).

Conclusion

This up-to-date systematic review highlights that once-weekly semaglutide treatment resulted in clinically important weight loss, becoming a promising adjuvant therapy for obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesObesityOverweightHumansInjections, SubcutaneousHypoglycemic AgentsAdultWeight LossRandomized Controlled Trials as TopicSemaglutide

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsSemaglutide

Autor:innen und Institutionen

  • Responsabilidade Social. Hospital Moinhos de Vento. Porto Alegre/Brazil.
  • Núcleo de Avaliação de Tecnologias em Saúde. Hospital Universitário da Universidade da Grande Dourados. Dourados/Brazil.
  • Núcleo de Avaliação de Tecnologias em Saúde - Hospital Universitário da Universidade Federal de São Carlos. São Carlos/Brazil.
  • Centro de Informação Sobre Medicamentos. Secretaria de Saúde do Estado da Bahia. Salvador/Brazil.
  • Instituto Capixaba de Ensino, Pesquisa e Inovação em Saúde (ICEPi), Vitória, ES, Brazil.

Förderung

  • Ministério da Saúde

Zitieren

APA

Dorneles, G., Algeri, E., Lauterbach, G., Pereira, M., & Fernandes, B. (2024). Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis. Experimental and Clinical Endocrinology & Diabetes, 132(06), 316-327. https://doi.org/10.1055/a-2303-8558

Vancouver

Dorneles G, Algeri E, Lauterbach G, Pereira M, Fernandes B. Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis. Experimental and Clinical Endocrinology & Diabetes. 2024;132(06):316-327. doi:10.1055/a-2303-8558

BibTeX
@article{Dorneles2024,
  author = {Dorneles, Gilson and Algeri, Ellen and Lauterbach, Gerhard and Pereira, Marcelo and Fernandes, Brigida},
  title = {Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis},
  journal = {Experimental and Clinical Endocrinology & Diabetes},
  year = {2024},
  volume = {132},
  number = {06},
  pages = {316--327},
  doi = {10.1055/a-2303-8558}
}
Kostenlos starten →